Tumor Necrosis Factor α Inhibitor-Induced Lupuslike Syndrome in a Patient Prescribed Certolizumab Pegol

Cutis. 2022 Jun;109(6):E18-E21. doi: 10.12788/cutis.0554.

Authors

David Walton Crasto Jr¹, Loren Touma¹, David Roy¹

Affiliation

¹ Drs. Crasto and Touma are from the College of Osteopathic Medicine, William Carey University, Hattiesburg, Mississippi. Dr. Roy is from Pine Belt Dermatology and Skin Cancer Center, Biloxi, Mississippi.

PMID: 35960967
DOI: 10.12788/cutis.0554

No abstract available

Publication types

Letter

MeSH terms

Certolizumab Pegol / adverse effects
Humans
Immunoglobulin Fab Fragments* / pharmacology
Immunologic Factors
Polyethylene Glycols / adverse effects
Tumor Necrosis Factor-alpha*

Substances

Immunoglobulin Fab Fragments
Immunologic Factors
Tumor Necrosis Factor-alpha
Polyethylene Glycols
Certolizumab Pegol